The Fecal Calprotectin Test Market Size was valued at USD 140.2 Mn in 2023 and is predicted to reach USD 280.5 Mn by 2031 at a 9.17% CAGR during the forecast period for 2024-2031.
Fecal calprotectin testing can identify gastrointestinal inflammation. A protein called calprotectin is secreted by white blood cells when inflammation occurs. Several factors drive the global fecal calprotectin test industry forward, including healthcare providers' and patients' growing recognition of non-invasive testing procedures. The diagnostic tools market is being driven by technological improvements that improve the accuracy and efficiency of tests. Another factor driving the popularity of fecal calprotectin tests is the growing availability of home testing kits and the focus on preventative healthcare.
The factor fueling the global rise of the fecal calprotectin test market is the cooperation between research organizations, academic institutions, and industry players. Moreover, companies in the fecal calprotectin test industry work with medical professionals, labs specialising in diagnostics, and universities to create and sell cutting-edge testing products. Overall, the industry is growing due to these alliances, which boost product innovation, guarantee regulatory compliance, and increase market growth.
However, the high cost of testing and the lack of knowledge among patients and healthcare providers are the main factors limiting the market for fecal calprotectin tests, preventing their widespread acceptance and accessibility. In addition, the fecal calprotectin test market was affected by the COVID-19 pandemic because it limited patient visits to healthcare institutions and caused delays in standard diagnostic processes. However, the market was able to bounce back because of rising demand for non-invasive home testing kits and persistent emphasis on early diagnosis and management of gastrointestinal diseases. Market growth is attributable to increasing investments and technological developments in the fecal calprotectin test market.
Competitive Landscape
Some of the Major Key Players in the Fecal Calprotectin Test Market are
- Abbexa
- ALPCO
- Alpha Laboratories
- Biomerica
- BÜHLMANN Laboratories AG
- DRG Instruments GmbH
- EagleBio
- Epitope Diagnostics, Inc.
- OPERON, S.A.
- R-Biopharm AG
- Svar Life Science
- Thermo Fisher Scientific Inc.
- Werfen
- SENTINEL CH. SpA
- Diazyme Laboratories, Inc.
- DiAgam
Market Segmentation:
The fecal calprotectin test market is segmented based on patient type, assay type, indication, and end-user. Based on patient type, the market is segmented into adult and pediatric. The market is segmented by assay type into ELISA (Enzyme-linked Immunosorbent Assay), enzyme fluoroimmunoassay, and quantitative immune chromatography. By indication, the market is segmented into inflammatory bowel disease, colorectal cancer, and celiac disease. The market is segmented by end-user into hospitals, diagnostic laboratories, and academic & research institutes.
Based on the Patient Type, the Adult Fecal Calprotectin Test Segment is Accounted as a Major Contributor to the Fecal Calprotectin Test Market
The adult fecal calprotectin test market is expected to hold a major global market share in 2023 due to the great frequency of adult gastrointestinal disorders, including ulcerative colitis and Crohn’s disease. Early diagnosis and growing knowledge of these diseases fuel the need for non-invasive diagnostic approaches. Further driving of this segment development includes the increasing frequency of colorectal cancer screenings and the need to monitor chronic inflammatory bowel illnesses efficiently.
Diagnostic Laboratories Segment to Witness Growth at a Rapid Rate
Diagnostic laboratories are growing because there is a growing need for non-invasive diagnostic instruments that can accurately identify gastrointestinal illnesses. Having trustworthy testing procedures is crucial due to the increasing number of cases of Crohn’s disease, ulcerative colitis, and colon cancer. Additionally, diagnostic laboratories that offer fecal calprotectin tests are on the rise, which is a good thing because diagnostic laboratory technology is always improving and because people are starting to pay more attention to the importance of early diagnosis and preventative healthcare, growing this segment.
In the Region, the North American Fecal Calprotectin Test Market Holds a Significant Revenue Share
The North American fecal calprotectin test market is expected to register the highest market share in revenue in the near future because of improvements in healthcare, a rise in the number of gastrointestinal illnesses, and a greater emphasis on the need for early detection. The presence of top diagnostic firms and heavy investment in R&D also contribute to the region’s booming market. In addition, Asia Pacific is projected to grow rapidly in the global fecal calprotectin test market because of the widespread nature of gastrointestinal problems, the ever-increasing cost of healthcare, and the expanding knowledge of alternatives to invasive diagnostic procedures.
Moreover, contributing to the region’s market growth are expanding healthcare infrastructure and large investments in medical research in the Asia Pacific region.
Recent Developments:
- In May 2024, ALPCO-GeneProof, a world leader in molecular diagnostics, and Revvity’s EUROIMMUN division, a top producer of in-vitro diagnostic products, established a strategic alliance to increase the availability of GeneProof PCR kits across the EU. As a result of this partnership, the cutting-edge molecular diagnostic technologies developed by ALPCO-GeneProof will be combined with EUROIMMUN’s vast distribution network and support infrastructure.
- In May 2024, Epitope Diagnostics, Inc. introduced its fully automated chemiluminescent immunoassay devices (ECL25 and ECL100) along with panel kits that include both common and specialized chemiluminescent immunoassay tests for a range of clinical types.
Fecal Calprotectin Test Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 140.2 Mn |
|
Revenue Forecast In 2031 |
USD 280.5 Mn |
|
Growth Rate CAGR |
CAGR of 9.17% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Patient Type, By Assay Type, By Indication, By End-user and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Abbexa, ALPCO, Alpha Laboratories, Biomerica, BÜHLMANN Laboratories AG, DRG INSTRUMENTS GMBH, EagleBio, Epitope Diagnostics, Inc., OPERON, S.A., R-Biopharm AG, Svar Life Science, Thermo Fisher Scientific, Inc., Werfen, SENTINEL CH. SpA, Diazyme Laboratories, Inc., and DiAgam. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
